样式: 排序: IF: - GO 导出 标记为已读
-
Scottish Parliament votes to increase minimum unit price for alcohol Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-30 Udani Samarasekera
-
Urgent action needed to achieve viral hepatitis elimination Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-23 The Lancet Gastroenterology & Hepatology
-
Managing irritable bowel syndrome: balancing diet and pharmacotherapy Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-18 Uday C Ghoshal, Uzma Mustafa, Mahesh K Goenka
-
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-18 Sanna Nybacka PhD, Hans Törnblom MD, Axel Josefsson MD, Johann P Hreinsson MD, Lena Böhn PhD, Åsa Frändemark MD, Cecilia Weznaver MSc, Stine Störsrud PhD, Prof Magnus Simrén MD
Dietary advice and medical treatments are recommended to patients with irritable bowel syndrome (IBS). Studies have not yet compared the efficacy of dietary treatment with pharmacological treatment targeting the predominant IBS symptom. We therefore aimed to compare the effects of two restrictive dietary treatment options versus optimised medical treatment in people with IBS. This single-centre, single-blind
-
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-16 Gareth C Parkes, Charlotte R H Hedin
-
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-16 Neil Chanchlani PhD, Simeng Lin PhD, Claire Bewshea MSc, Benjamin Hamilton MBBS, Amanda Thomas MBBS, Rebecca Smith BMBS, Christopher Roberts MBBS, Maria Bishara BMBS, Rachel Nice MSc, Prof Charlie W Lees PhD, Prof Shaji Sebastian MD, Prof Peter M Irving MD, Prof Richard K Russell PhD, Prof Timothy J McDonald PhD, James R Goodhand MBBS, Tariq Ahmad DPhil, Nicholas A Kennedy PhD, PANTS Consortium, Vinod
We sought to report the effectiveness of infliximab and adalimumab over the first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and the strategies that prevent or mitigate loss of response. Personalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting the rates of effectiveness of infliximab
-
WHO 2024 hepatitis B guidelines: an opportunity to transform care Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-10 Philippa J Easterbrook, Niklas Luhmann, Sahar Bajis, Myat Sandi Min, Morkor Newman, Olufunmilayo Lesi, Meg C Doherty
-
-
Addressing the evolving landscape of global malnutrition Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 The Lancet Gastroenterology & Hepatology
-
-
Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Mads Israelsen, Mary E Rinella, Aleksander Krag
-
NORPACT-1: implications for future trials – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Knut Jørgen Labori, Svein Olav Bratlie, Svein Dueland, Kristoffer Lassen
-
Has the time come for a systematic top-down approach in Crohn's disease? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Mathurin Fumery, Anthony Buisson
-
NORPACT-1: implications for future trials Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Rebecca A Snyder, Matthew H G Katz
-
Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Yu Wu, Fei Fang
-
A women-focused matrix mentorship programme in gastroenterology Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Jalpa Devi, Kathryn Hutchins, Dawn Sears, Anita Afzali, Aline Charabaty
-
Microbiota therapeutics for inflammatory bowel disease: the way forward Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Lukas Bethlehem PhD, Maria Manuela Estevinho MD, Ari Grinspan MD, Prof Fernando Magro PhD, Jeremiah J Faith PhD, Prof Jean-Frederic Colombel MD
Microbiota therapeutics that transplant faecal material from healthy donors to people with mild-to-moderate ulcerative colitis have shown the potential to induce remission in about 30% of participants in small, phase 2 clinical trials. Despite this substantial achievement, the field needs to leverage the insights gained from these trials and progress towards phase 3 clinical trials and drug approval
-
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Serena Porcari MD, William Fusco MD, Igor Spivak MD PhD, Marcello Fiorani MD, Antonio Gasbarrini MD, Eran Elinav MD PhD, Giovanni Cammarota MD, Gianluca Ianiro MD PhD
The gut microbiome is acknowledged as a key determinant of human health, and technological progress in the past two decades has enabled the deciphering of its composition and functions and its role in human disorders. Therefore, manipulation of the gut microbiome has emerged as a promising therapeutic option for communicable and non-communicable disorders. Full exploitation of current therapeutic microbiome
-
Liver cancer surveillance in people with hepatitis B in Africa Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-06 Dennis A Ndububa
-
Hepatocellular carcinoma surveillance among people living with hepatitis B in Senegal (SEN-B): insights from a prospective cohort study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-06 Adrià Ramírez Mena MD, Mbaye Thiam MD, Daye Ka MD, Ibrahima Niang MD, Judicaël Tine MD, Louise Fortes MD, Kiné Ndiaye MD, Ousseynou Ndiaye PhD, Maguette Fall MD, Assietou Gaye MD, Ndeye Fatou Ngom PhD, Fatou Fall MD, Prof Annalisa Berzigotti PhD, Gregory Dale Kirk PhD, Antoine Jaquet PhD, Prof Moussa Seydi MD, Gilles Wandeler MD, SEN-B investigators
Chronic hepatitis B virus (HBV) infection is the predominant cause of hepatocellular carcinoma in west Africa, yet data on the incidence of HBV-related hepatocellular carcinoma remain scarce. We aimed to describe the uptake and early outcomes of systematic ultrasound-based hepatocellular carcinoma screening in SEN-B, which is a prospective HBV cohort in Senegal. In this prospective cohort study, we
-
Ecogastroenterology: cultivating sustainable clinical excellence in an environmentally conscious landscape Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-27 Kassem Sharif MD, Enrique Rodriguez de Santiago MD, Paula David MD, Prof Arnon Afek MD, Prof Ian M Gralnek MD, Prof Shomron Ben-Horin MD, Prof Adi Lahat MD
Gastrointestinal practices, especially endoscopy, have a substantial environmental impact, marked by notable greenhouse gas emissions and waste generation. As the world struggles with climate change, there emerges a pressing need to re-evaluate and reform the environmental footprint within gastrointestinal medicine. The challenge lies in finding a harmonious balance between ensuring clinical effectiveness
-
US Government, states reign in insurers' prior authorisation Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-20 Bryant Furlow
-
Local ablation in pancreatic cancer: some answers and more questions Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-19 Zachary T Berman, Rebekah R White
-
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-19 Florentine E F Timmer MD, Bart Geboers MD, Alette H Ruarus MD, Laurien G P H Vroomen MD, Evelien A C Schouten MSc, Susan van der Lei MD, Danielle J W Vos MD, Madelon Dijkstra MD, Hannah H Schulz MD, Joyce Bakker BSc, Bente A T van den Bemd MD, Petrousjka M van den Tol MD, Robbert S Puijk MD, Birgit I Lissenberg-Witte PhD, Prof Tanja D de Gruijl PhD, Jan J J de Vries MD, Frank J Lagerwaard MD, Hester
Pancreatic ductal adenocarcinoma is an aggressive disease with a dismal prognosis. Stage III locally advanced pancreatic cancer is considered unresectable and current palliative chemotherapy regimens only modestly improve survival. Guidelines suggest chemoradiation or stereotactic ablative body radiotherapy (SABR) could be beneficial in certain circumstances. Other local treatments such as irreversible
-
Should a no-drain policy after distal pancreatectomy become standard? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-16 Ulla Klaiber, Oliver Strobel
-
Prophylactic abdominal drainage after distal pancreatectomy (PANDORINA): an international, multicentre, open-label, randomised controlled, non-inferiority trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-16 Eduard A van Bodegraven MD, Alberto Balduzzi MD, Tess M E van Ramshorst MD, Prof Giuseppe Malleo MD, Frederique L Vissers MD, Jony van Hilst MD, Sebastiaan Festen MD, Prof Mohammad Abu Hilal MD, Prof Horacio J Asbun MD, Nynke Michiels MD, Prof Bas Groot Koerkamp MD, Prof Olivier R C Busch MD, Freek Daams MD, Prof Misha D P Luyer MD, Marco Ramera MD, Giovanni Marchegiani MD, Prof Joost M Klaase MD,
Prophylactic passive abdominal drainage is standard practice after distal pancreatectomy. This approach aims to mitigate the consequences of postoperative pancreatic fistula (POPF) but its added value, especially in patients at low risk of POPF, is currently being debated. We aimed to assess the non-inferiority of a no-drain policy in patients after distal pancreatectomy. In this international, multicentre
-
Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-13 Raghav Sundar, Elizabeth C Smyth
-
-
You Are What You Eat: a Twin Experiment Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 H, o, l, l, i, e, , S, h, e, r, w, o, o, d, -, M, a, r, t, i, n
-
Research in Brief Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 H, o, l, l, y, , B, a, k, e, r
-
Resmetirom for NASH: balancing promise and prudence Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 T, h, e, , L, a, n, c, e, t, , G, a, s, t, r, o, e, n, t, e, r, o, l, o, g, y, , &, , H, e, p, a, t, o, l, o, g, y
-
Gluten and non-coeliac gluten sensitivity: the nocebo effect and future avenues – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Marlijne C G de Graaf, Daniel Keszthelyi, Fred J P H Brouns, Louise Dye, Daisy M A E Jonkers, on behalf of all authors
-
The DESTIN trial: to step up or not? – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Ji Young Bang, Shyam Varadarajulu
-
The DESTIN trial: to step up or not? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Oscar Cahyadi, Vinay Dhir, John Leeds, Enrique de-Madaria, Nadeem Tehami
-
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Xiang-Lei Yuan, Bing Hu
-
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Daisuke Murakami, Masayuki Yamato, Takayoshi Nishino, Makoto Arai
-
The DESTIN trial: to step up or not? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Avinash Tiwari, Mayank Mehrotra, Ajmal Hasan, Jaya Agarwal, Gaurav Kumar Singh
-
Gluten and non-coeliac gluten sensitivity: the nocebo effect and future avenues Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-06 Maurizio Mennini, Federica Ferrari, Pasquale Parisi, Giovanni Di Nardo
-
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-28 Paul N Brennan MRCP, Oliver D Tavabie MRCP, Wenhao Li PhD, Thomas Marjot MRCP, Lynsey Corless PhD, Prof Jonathan A Fallowfield PhD, Helen Jarvis MSc, Dina Mansour MBBS, Stuart McPherson PhD, Prof William Rosenberg DPhil, Karen Rockell, Prof Jeremy Tomlinson PhD, Andrew Yeoman MD, Prof Emmanuel A Tsochatzis PhD, Prof John F Dillon MD, Prof William Alazawi PhD, Kushala W M Abeysekera PhD
The American, European, and Latin American liver societies have proposed a change in the nomenclature we use to describe alcohol-related liver disease and non-alcoholic fatty liver disease. Additionally, a term encompassing both is now advocated: steatotic liver disease, which includes metabolic dysfunction associated steatotic liver disease (MASLD) and MASLD with greater alcohol consumption (MetALD)
-
Robotic pancreatoduodenectomy: preparing for the future Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-28 Elisa Bannone, Giovanni Marchegiani
-
Effect of robotic versus open pancreaticoduodenectomy on postoperative length of hospital stay and complications for pancreatic head or periampullary tumours: a multicentre, open-label randomised controlled trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-28 Prof Qu Liu MD, Mengyang Li MD, Prof Yuanxing Gao MD, Prof Tao Jiang MD, Prof Bing Han MD, Prof Guodong Zhao MD, Chao Lin MD, Prof Wan Yee Lau MD, Prof Zhiming Zhao MD, Prof Rong Liu MD
The flexibility of the robotic system in resection and reconstruction provides potential benefits in pancreaticoduodenectomy. Increasingly, robotic pancreaticoduodenectomy (RPD) has been reported with favourable outcomes, but high-level evidence is still scarce. We aimed to compare the short-term postoperative outcomes of RPD with those of open pancreaticoduodenectomy (OPD), and hypothesised that postoperative
-
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-22 Nurulamin M Noor PhD, James C Lee PhD, Simon Bond PhD, Francis Dowling BSc, Biljana Brezina MSc, Kamal V Patel MRCP, Tariq Ahmad DPhil, Paul J Banim MD, James W Berrill MD, Rachel Cooney DPhil, Juan De La Revilla Negro MD, Shanika de Silva MRCP, Shahida Din PhD, Dharmaraj Durai PhD, John N Gordon DM, Prof Peter M Irving MD, Matthew Johnson MD, Alexandra J Kent DPhil, Klaartje B Kok PhD, Prof Gordon
Management strategies and clinical outcomes vary substantially in patients newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker to guide therapy by assessing outcomes in patients randomised to either top-down (ie, early combined immunosuppression with infliximab and immunomodulator) or accelerated step-up (conventional) treatment strategies. PROFILE (PRedicting
-
Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-22 Thomas P Chapman, Tariq Ahmad, Jack Satsangi
-
Can genetically engineered pig livers offer patients precious time? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-16 B, r, y, a, n, t, , F, u, r, l, o, w
-
Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Nicolas Minier PhD, Alice Nanelin Guingané PhD, Prof Edith Okeke MD, Edford Sinkala MD, Asgeir Johannessen PhD, Monique I Andersson MD, Pantong Davwar MD, Prof Hailemichael Desalegn PhD, Mary Duguru MD, Prof Fatou Fall MD, Prof Souleyman Mboup PhD, Tongai Maponga PhD, Prof Philippa C Matthews PhD, Adrià Ramírez Mena MD, Gibril Ndow PhD, Stian M S Orlien PhD, Nicholas Riches MBChB, Prof Moussa Seydi
Hepatitis B virus (HBV) elimination requires expanding and decentralising HBV care services. However, peripheral health facilities lack access to diagnostic tools to assess eligibility for antiviral therapy. Through the Hepatitis B in Africa Collaborative Network (HEPSANET), we aimed to develop and evaluate a score using tests generally available at lower-level facilities, to simplify the evaluation
-
A new tool for assessing hepatitis B treatment eligibility in Africa Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Serge Ouoba, Moussa Lingani
-
WHO hepatitis C elimination targets: the global equity challenge Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Katherine Heath, Andrew Hill
-
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Prof Alison D Marshall PhD, Alex R Willing BAdvSci, Abe Kairouz BPysch, Evan B Cunningham PhD, Alice Wheeler BPysch, Nicholas O’Brien MPH, Vidura Perera MPH, John W Ward MD, Lindsey Hiebert MPH, Prof Louisa Degenhardt PhD, Behzad Hajarizadeh PhD, Samantha Colledge PhD, Prof Matthew Hickman PhD, Danielle Jawad MPH, Prof Jeffrey V Lazarus PhD, Prof Gail V Matthews PhD, Andrew Scheibe MD, Prof Peter Vickerman
Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have delivered high response rates (>95%) and simplified the management of HCV treatment, permitting non-specialists to manage patients without advanced liver disease. We collected and reviewed global data on the registration and reimbursement (government subsidised) of HCV therapies, including restrictions on reimbursement. Primary
-
Eliminating viral hepatitis: no room for complacency Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 R, o, b, , B, r, i, e, r, l, e, y
-
Harnessing the power of civil society to achieve hepatitis elimination Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Danjuma Adda, Jessica Hicks, Cary James, Alexandra Smith
-
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Prof Graham S Cooke DPhil, Barnaby Flower PhD, Evan Cunningham PhD, Alison D Marshall PhD, Prof Jeffrey V Lazarus PhD, Adam Palayew PhD, Prof Jidong Jia MD PhD, Prof Rakesh Aggarwal MD DM, Prof Mamum Al-Mahtab PhD, Prof Yashuito Tanaka PhD, Prof Sook-Hyang Jeong PhD, Kittiyod Poovorawan MD, Prof Imam Waked PhD, Lindsey Hiebert MPH, Pham M Khue PhD, Prof Jason Grebely PhD, Prof Diana Alcantara-Payawal
The top 20 highest burdened countries (in disability-adjusted life years) account for more than 75% of the global burden of viral hepatitis. An effective response in these 20 countries is crucial if global elimination targets are to be achieved. In this update of the Commission on accelerating the elimination of viral hepatitis, we convene national experts from each of the top 20 highest burdened countries
-
Africa CDC's viral hepatitis prevention and control programme: a continental initiative to support elimination programmes Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Hanna Amanuel Tesfahunei, Mohammed Abdulaziz, Nafiisah Chotun, John W Ward, Mohamed Hassany, Jean Kaseya
-
Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-15 Marion Delphin PhD, Khadija Said Mohammed MSc, Louise O Downs MBBS, Sheila F Lumley BMBCh, Elizabeth Waddilove MSc, Dorcas Okanda MSc, Nadia Aliyan MD, Marije Van Schalkwyk MD, Motswedi Anderson PhD, Ponsiano Ocama PhD, Tongai Maponga PhD, Judith Torimiro PhD, Prof Collins Iwuji MD, Prof Thumbi Ndung'u PhD, Prof Philippa C Matthews DPhil, Jantjie Taljaard MMed
The WHO African region bears a disproportionate burden of morbidity and mortality related to chronic hepatitis B virus (HBV) infection and accounts for an estimated 70% of new HBV infections worldwide. We investigated the extent to which HBV clinical trials represented populations in this region by searching the WHO International Clinical Trials Registry Platform and for interventional clinical trials
-
The COSMIC-312 study: will it shape future combination therapies for advanced hepatocellular carcinoma? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-13 Anna Saborowski, Ana Lleo
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-13 Thomas Yau MD, Prof Ahmed Kaseb MD, Prof Ann-Lii Cheng MD, Prof Shukui Qin MD, Prof Andrew X Zhu MD, Prof Stephen L Chan MD, Tamar Melkadze MD, Wattana Sukeepaisarnjaroen MD, Valery Breder MD, Gontran Verset MD, Prof Edward Gane MD, Prof Ivan Borbath MD, Jose David Gomez Rangel MD, Prof Baek-Yeol Ryoo MD, Tamta Makharadze MD, Prof Philippe Merle MD, Fawzi Benzaghou MD, Steven Milwee PharmD, Zhong Wang
The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. In the initial analysis, cabozantinib plus atezolizumab significantly prolonged progression-free survival versus sorafenib. Here, we report the pre-planned final overall survival analysis and updated safety and efficacy results following
-
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Prof James O Lindsay PhD, Prof Daniel Hind PhD, Lizzie Swaby MSc, Hannah Berntsson MSc, Mike Bradburn MSc, Uday Bannur C FRCR, Jennifer Byrne PhD, Christopher Clarke FRCR, Lauren Desoysa MSc, Ben Dickins PhD, Shahida Din MBChB, Prof Richard Emsley PhD, Gemma A Foulds PhD, Prof John Gribben MD DSc, Prof Christopher Hawkey DM, Prof Peter M Irving MD, Majid Kazmi MBChB, Ellen Lee MSc, Amanda Loban PhD
A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to assess the safety and efficacy of HSCT with an immune-ablative regimen of reduced intensity versus standard of care in this patient population. This open-label, multicentre, randomised controlled
-
Thank you to The Lancet Gastroenterology & Hepatology's statistical and peer reviewers in 2023 Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07
-
Rusfertide for iron overload in haemochromatosis – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Kris V Kowdley, Nishit B Modi, Frank H Valone
-
An International Classification of Diseases code for gastric intestinal metaplasia: an opportunity for gastric cancer prevention Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-02-07 Robert J Huang, M Constanza Camargo
-